These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
232 related articles for article (PubMed ID: 7514710)
41. Precipitation of spinally mediated withdrawal signs by intrathecal administration of naloxone and the mu-receptor antagonist CTP in morphine-dependent mice. Shook J; Kazmierski W; Hruby V; Burks T NIDA Res Monogr; 1988; 81():143-8. PubMed ID: 2900467 [TBL] [Abstract][Full Text] [Related]
42. Do pharmacological approaches that prevent opioid tolerance target different elements in the same regulatory machinery? Garzón J; Rodríguez-Muñoz M; Sánchez-Blázquez P Curr Drug Abuse Rev; 2008 Jun; 1(2):222-38. PubMed ID: 19630721 [TBL] [Abstract][Full Text] [Related]
43. The role of nitric oxide in the development of opioid withdrawal induced by naloxone after acute treatment with mu- and kappa-opioid receptor agonists. Capasso A; Sorrentino L; Pinto A Eur J Pharmacol; 1998 Oct; 359(2-3):127-31. PubMed ID: 9832382 [TBL] [Abstract][Full Text] [Related]
44. Mu-opioid receptor up-regulation and functional supersensitivity are independent of antagonist efficacy. Sirohi S; Kumar P; Yoburn BC J Pharmacol Exp Ther; 2007 Nov; 323(2):701-7. PubMed ID: 17698975 [TBL] [Abstract][Full Text] [Related]
45. Is morphine dependence mediated exclusively by the Mu receptor? Adams RE; Wooten GF Neurochem Res; 1993 Oct; 18(10):1041-5. PubMed ID: 8255352 [TBL] [Abstract][Full Text] [Related]
46. Etonitazene-induced antinociception in mu1 opioid receptor deficient CXBK mice: evidence for a role for mu2 receptors in supraspinal antinociception. Connelly CD; Martinez RP; Schupsky JJ; Porreca F; Raffa RB Life Sci; 1994; 54(21):PL369-74. PubMed ID: 7910928 [TBL] [Abstract][Full Text] [Related]
47. Tolerance to mu-opioid agonists in human neuroblastoma SH-SY5Y cells as determined by changes in guanosine-5'-O-(3-[35S]-thio)triphosphate binding. Elliott J; Guo L; Traynor JR Br J Pharmacol; 1997 Aug; 121(7):1422-8. PubMed ID: 9257923 [TBL] [Abstract][Full Text] [Related]
48. The ontogeny of mu opiate tolerance and dependence in the rat: antinociceptive and biochemical studies. Windh RT; Little PJ; Kuhn CM J Pharmacol Exp Ther; 1995 Jun; 273(3):1361-74. PubMed ID: 7791109 [TBL] [Abstract][Full Text] [Related]
49. Antisense oligodeoxynucleotides to opioid mu and delta receptors reduced morphine dependence in mice: role of delta-2 opioid receptors. Sánchez-Blázquez P; García-Espãna A; Garzón J J Pharmacol Exp Ther; 1997 Mar; 280(3):1423-31. PubMed ID: 9067332 [TBL] [Abstract][Full Text] [Related]
50. Differences in physical dependence induced by selective mu or delta opioid agonists and by endogenous enkephalins protected by peptidase inhibitors. Maldonado R; Feger J; Fournié-Zaluski MC; Roques BP Brain Res; 1990 Jun; 520(1-2):247-54. PubMed ID: 2169953 [TBL] [Abstract][Full Text] [Related]
51. Differential regulation of mu and delta opiate receptors by morphine, selective agonists and antagonists and differentiating agents in SH-SY5Y human neuroblastoma cells. Zadina JE; Harrison LM; Ge LJ; Kastin AJ; Chang SL J Pharmacol Exp Ther; 1994 Sep; 270(3):1086-96. PubMed ID: 7932156 [TBL] [Abstract][Full Text] [Related]
52. [Different roles of the spinal protein kinase C alpha and gamma in morphine dependence and naloxone-precipitated withdrawal]. Cao JL; Ding HL; He JH; Zhang LC; Wang JK; Zeng YM Sheng Li Xue Bao; 2005 Apr; 57(2):161-8. PubMed ID: 15830100 [TBL] [Abstract][Full Text] [Related]
53. Mu opiate receptor down-regulation by morphine and up-regulation by naloxone in SH-SY5Y human neuroblastoma cells. Zadina JE; Chang SL; Ge LJ; Kastin AJ J Pharmacol Exp Ther; 1993 Apr; 265(1):254-62. PubMed ID: 8097244 [TBL] [Abstract][Full Text] [Related]
54. Ultra-low dose naloxone restores the antinociceptive effect of morphine in pertussis toxin-treated rats by reversing the coupling of mu-opioid receptors from Gs-protein to coupling to Gi-protein. Tsai RY; Tai YH; Tzeng JI; Cherng CH; Yeh CC; Wong CS Neuroscience; 2009 Dec; 164(2):435-43. PubMed ID: 19682558 [TBL] [Abstract][Full Text] [Related]
55. Cholecystokinin receptor-1 mediates the inhibitory effects of exogenous cholecystokinin octapeptide on cellular morphine dependence. Wen D; Ma CL; Zhang YJ; Meng YX; Ni ZY; Li SJ; Cong B BMC Neurosci; 2012 Jun; 13():63. PubMed ID: 22682150 [TBL] [Abstract][Full Text] [Related]
56. Morphine can produce analgesia via spinal kappa opioid receptors in the absence of mu opioid receptors. Yamada H; Shimoyama N; Sora I; Uhl GR; Fukuda Y; Moriya H; Shimoyama M Brain Res; 2006 Apr; 1083(1):61-9. PubMed ID: 16530171 [TBL] [Abstract][Full Text] [Related]
57. Enhancement of morphine withdrawal signs in the rat after chronic treatment with naloxone. Suzuki T; Fukagawa Y; Misawa M Eur J Pharmacol; 1990 Mar; 178(2):239-42. PubMed ID: 2158457 [TBL] [Abstract][Full Text] [Related]
58. RP 67580, a selective antagonist of neurokinin-1 receptors, modifies some of the naloxone-precipitated morphine withdrawal signs in rats. Maldonado R; Girdlestone D; Roques BP Neurosci Lett; 1993 Jun; 156(1-2):135-40. PubMed ID: 7692360 [TBL] [Abstract][Full Text] [Related]
59. Effect of repeated administration of morphine on the activity of extracellular signal regulated kinase in the mouse brain. Narita M; Ioka M; Suzuki M; Narita M; Suzuki T Neurosci Lett; 2002 May; 324(2):97-100. PubMed ID: 11988336 [TBL] [Abstract][Full Text] [Related]